Medical innovation is slow and costly. We spend several billion dollars and 10 to 15 years to get 1 new molecule approved. This is the result of a high rate of delays and failures, many of which can be avoided by making better decisions.
Our team is building AI-powered technology to help development teams make the right decisions at the right time. By reducing risks, we want to encourage more innovation and help bring patients more options sooner.
The ultimate objective of every development plan is to demonstrate the safety and efficacy profile of the product in a way that meets the expectations of the health authorities. Information necessary to understand these expectations is inaccessible.
Our team is using AI to provide development teams with instant evidence-backed answers to all their regulatory questions.
Long Term Goal
Our goal is to build AI systems that learn from historical development programs to evaluate options, calculate risks, and make recommendations. Our technology will integrate seamlessly with established workflows to deliver insights in real time.
Co-Founder & CEO
Amin brings 10 years of business development experience in the pharmaceutical and contract research industry. He has helped North American and European small to medium-sized companies access the US and Canadian markets, increase their revenues and establish strategic partnerships. He has negotiated and secured agreements with a number of Fortune 500 companies. While working with biopharmaceutical and medical device clinical development teams, Amin became passionate about addressing the delays and failures that make medical innovation unsustainable. He is a McGill University B.Sc. graduate in Biology and a Concordia University M.Sc. graduate in Cell & Molecular Biology.
Co-Founder & CTO